Endpoints for Clinical Trials in Young Children with Cystic Fibrosis

The availability of sensitive, reproducible, and feasible outcome measures for quantifying lung disease in children with cystic fibrosis (CF) younger than 6 years is critical to the conduct of clinical trials in this important population. Historically, identifying and quantifying the presence of lun...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Davis, Stephanie D., Brody, Alan S., Emond, Mary J., Brumback, Lyndia C., Rosenfeld, Margaret
Formato: Artigo
Lenguaje:Inglês
Publicado: American Thoracic Society 2007
Materias:
Symposium: Measures for Development of New Therapies in Cystic Fibrosis
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2647606/
https://ncbi.nlm.nih.gov/pubmed/17652509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1513/pats.200703-041BR
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares